CASE REPORT

Article in PDF format - JOP Home page

JOP. J Pancreas (Online) 2006; 7(3):306-310.

Gemcitabine-Induced Rectus Abdominus Radiation Recall

Marwan G Fakih1,2

1Department of Medicine, Roswell Park Cancer Institute; 2Department of Medicine, University at Buffalo School of Medicine and Biomedical Sciences. Buffalo, NY, USA

ABSTRACT

Context Radiation recall has been described in the context of gemcitabine chemotherapy. However, this phenomenon has been largely limited to skin.

Case report We hereby report a case of radiation recall dermatitis and myositis occurring on gemcitabine monotherapy, five months after completing chemoradiation for locally advanced pancreatic cancer. Radiation recall resolved spontaneously with withdrawal of gemcitabine.

Conclusions This is the second case report that describes gemcitabine-induced radiation recall in rectus abdominus muscles after gemcitabine-based radiation therapy. Given the wide use of gemcitabine following chemoradiation for pancreatic cancer, providers should be aware of this potential complication.


INTRODUCTION

Pancreatic cancer is the fifth leading cause of cancer-related deaths in both men and women [1]. Less than 10% of newly diagnosed pancreatic cancers achieve 5-year survival. This grim prognosis is largely related to the advanced nature and unresectability of the tumor at the time of diagnosis. The median survival, with treatment, of patients with locally advanced disease has been limited to less than 1 year while the median survival of patients with metastatic disease has typically ranged between 5 and 7 months [2].

Recent efforts have focused on increasing treatment efficacy of locally advanced pancreatic cancer by using newer combinations of chemotherapy and radiation. Gemcitabine, a nucleoside analogue with potent radiosensitizing activity, has been recently investigated with radiation in the treatment of this patient population. Encouraging median survivals compared to historical controls have been described; however, this has been at the expense of significant toxicity [3, 4, 5]. Crane et al. compared, in a retrospective study of 114 patients, the outcomes of locally advanced pancreatic cancers treated with either gemcitabine plus radiation to those treated with 5-flurouracil (5-FU) plus radiation [6]. Gemcitabine-based radiation was associated with a median survival of 11 months versus 9 months for the 5-FU-based radiation [6]. Toxicity requiring hospitalization more than 5 days occurred in 23% of patients receiving gemcitabine versus 2% of those receiving 5-FU [6]. M. D. Anderson Cancer Center (MDACC) also reported on the use of gemcitabine-based radiation in the neoadjuvant treatment of patients with locally advanced pancreatic cancer [7]. While the rate of successful resection was high at 73%, hospitalization rate secondary to chemoradiation occurred in 43% of patients due to gastrointestinal and hematological toxicities [7].

While gastrointestinal toxicities have been commonly reported with gemcitabine-based radiation in patients with pancreatic cancer, recall myositis has been previously reported only once in this setting [8]. We hereby report the second case of gemcitabine-induced radiation recall rectus abdominus myositis in a patient previously treated with gemcitabine-based chemoradiation.

CASE REPORT

A 52-year-old Caucasian man with history of chronic alcoholism and recurrent pancreatitis presented with persistent abdominal pain radiating to the back for two months. Upon further investigation he was found to have locally advanced pancreatic cancer with encasement of the mesenteric vessels (clinical stage T3N0M0). The diagnosis of adenocarcinoma of the pancreas was confirmed by computerized tomography (CT) guided biopsy. The patient did not have any personal or family history of dermatitis, myositis, or any skin disorder or muscular disorder. He was an active smoker of 1 pack per day and had quit drinking 5 years prior to this presentation. He denied any chemical exposures and had just retired from a technician job at a manufacturing company. His medication included fentanyl patch, oxycodone, gabapentin, and amitriptyline. These medications were introduced early on in his treatment for pain control (at the time of initiation of chemoradiation).

The patient was treated on a clinical protocol with continuous intravenous infusion (i.v.) of 5-FU (200 mg/m2/day for 5 days a week), weekly i.v. gemcitabine over 30 minutes at 200 mg/m2, and concurrent radiation therapy (1.8 Gy/fraction/day for a total of 50.4 Gy). The clinical target volume (CTV) for radiation included the gross tumor volume (GTV, defined by CT) expanded by 1.5 cm in all directions. An additional margin of at least 1 cm was added to the CTV for set up error and patient movement to constitute the planning target volume (PTV). An isocentrically-mounted linear accelerator with 18 MV photon energy was used to administer radiation. Chemoradiation was well tolerated without any major toxicities or delay in therapy. Post chemoradiation CT scans revealed a significant decrease in his pancreatic mass in association with a marked decrease in serum CA 19-9 levels. He received further consolidation chemotherapy with intravenous gemcitabine at 1,000 mg/m2/week over 30 minutes for 3 weeks every 4 week-cycle. During his fifth cycle of systemic chemotherapy he developed an erythematosus rash overlying a tender mass in the epigastrium (Figure 1, obtained after informed consent). No new medications, including topical ointments or creams, were introduced at the time of or prior to the development of these symptoms. There was no history of any prior chemical, mechanical, or thermal insult to the rectus abdominus area.

Figure 1. Well demarcated radiation recall dermatitis with evidence of rectus abdominis swelling (arrows).

 

A CT scan of the abdomen revealed an enlarged left and right rectus abdominus with areas of heterogeneity (Figure 2b) in comparison to baseline CT (Figure 2a). An ultrasound guided-biopsy failed to reveal any evidence of metastasis. This clinical inflammatory process (myositis and dermatitis) was attributed to gemcitabine-induced radiation recall. Gemcitabine was withheld and complete resolution of rectus abdominus myositis and overlying dermatitis followed. No other interventions such as glucocorticoids or anti-inflammatory drug use were implemented. Repeat CT scans confirmed complete resolution of the previously described abnormalities (Figure 2c). The patient was not challenged with any further gemcitabine therapy. He progressed within 2 months from his last gemcitabine dose with the development of liver metastases. He was treated on a phase I clinical trial with capecitabine, docetaxel, and cisplatin for a period of 6 months with eventual disease progression. During this period, he did not experience any further episodes of radiation recall dermatomysositis. He succumbed to his disease shortly after progressing on combination chemotherapy.

Figure 2. CT scan of the abdomen upon completion of chemoradiation (a.), at the time of radiation recall rectus abdominis myositis (b.), and after gemcitabine withdrawal (resolution of inflammatory process) (c.). White arrows point to the rectus abdominis (notably enlarged on picture b.)

 

DISCUSSION

Radiation recall is a phenomenon whereby radiation therapy followed by treatment with various drugs, such as chemotherapeutic agents, antitubercular drugs, tamoxifen, or exposure to ultraviolet light induces an inflammatory reaction in previously irradiated sites [9, 10, 11]. These reactions are most often cutaneous but have also been reported in other sites such as the lung, oral mucosa, intestine and central nervous system [12, 13, 14]. The exact mechanism of radiation recall is not known. Kitani et al. suggested that radiation therapy depletes the stem cells in the field of treatment rendering the irradiated tissue sensitive to future insults such as chemotherapy [15]. However, this theory remains largely unsubstantiated. Other theories include drug hypersensitivity and vascular damage as inducing factors. These, among others, have been reviewed elsewhere [16, 17].

Radiation recall reactions following gemcitabine was first described in the previously irradiated skin of a patient with breast cancer after two weeks from starting systemic gemcitabine therapy [18]. Multiple other cases of gemcitabine-induced radiation recall cutaneous reactions have been described since. However, gemcitabine-induced radiation recall in non-cutaneous sites have been rarely reported. One case of gemcitabine-induced radiation recall dermatitis and myositis of the upper thorax has been described in a patient with non-small cell lung cancer [19]. Another case series reported on 6 patients with gemcitabine-induced radiation recall in the central nervous system, gastrointestinal tract, lymphatic, and musculoskeletal systems [20]. This same case series included a case of radiation induced myositis in the rectus abdominus area after 5-FU based radiation therapy. Gemcitabine in these cases was given in i.v. 1,000 mg/m2 weekly regimens. The time between initiation of radiation and recall phenomenon ranged from 3 weeks to 8 months from the time gemcitabine was started [20].

Recently, Friedlander et al. reported on a case of rectus abdominus gemcitabine-induce radiation recall after gemcitabine-based chemoradiation for pancreatic cancer [8]. This reaction occurred after 3 months from completion of radiation therapy and resolved with corticosteroid treatment [8]. In our case, we observed radiation recall in the skin and rectus abdominus 5 months after the completion of chemoradiation and 4 months from initiation of consolidation gemcitabine therapy. This reaction resolved completely within 4 weeks from discontinuation of gemcitabine. The onset of our reaction was more delayed than the average of 56 days reported with prior gemcitabine radiation recall cases [8]. It is unclear if this reaction was primed by an exceptionally aggressive gemcitabine-based chemoradiation schedule. With gemcitabine being increasingly incorporated in both chemoradiation and chemotherapy of patients with locally advanced pancreatic cancer, oncologists and radiation oncologists should be aware of the possibility of such delayed reactions.

References

  1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002; 52:23-47. [More details]

  2. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15:2403-13. [More details]

  3. Wolff RA, Evans DB, Gravel DM, Lenzi R, Pisters PW, Lee JE, et al. Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Clin Cancer Res 2001; 7:2246-53. [More details]

  4. McGinn CJ, Zalupski MM, Shureiqi I, Robertson JM, Eckhauser FE, Smith DC, et al. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2001; 19:4202-8. [More details]

  5. McGinn CJ, Lawrence TS, Zalupski MM. On the development of gemcitabine-based chemoradiotherapy regimens in pancreatic cancer. Cancer 2002; 95(4 Suppl):933-40. [More details]

  6. Crane CH, Abbruzzese JL, Evans DB, Wolff RA, Ballo MT, Delclos M, et al. Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? Int J Radiat Oncol Biol Phys 2002; 52:1293-302. [More details]

  7. Wolff RA, Evans DB, Crane CH. Initial results of preoperative gemcitabine-based chemoradiation for respectable pancreatic adenocarcinoma. Proc Am Soc Clin Oncol 2002; Abstract 516. [More details]

  8. Friedlander PA, Bansal R, Schwartz L, Wagman R, Posner J, Kemeny N. Gemcitabine-related radiation recall preferentially involves internal tissue and organs. Cancer 2004; 100:1793-9. [More details]

  9. Extermann M, Vogt N, Forni M, Dayer P. Radiation recall in a patient with breast cancer treated for tuberculosis. Eur J Clin Pharmacol 1995; 48:77-8. [More details]

  10. Bostrom A, Sjolin-Forsberg G, Wilking N, Bergh J. Radiation recall: another call with tamoxifen. Acta Oncol 1999; 38:955-9. [More details]

  11. Del Guidice SM, Gerstley JK. Sunlight-induced radiation recall. Int J Dermatol 1988; 27:415-6. [More details]

  12. Schweitzer VG, Juillard GJ, Bajada CL, Parker RG. Radiation recall dermatitis and pneumonitis in a patient treated with paclitaxel. Cancer 1995; 76:1069-72. [More details]

  13. Eifel PJ, McClure S. Severe chemotherapy-induced recall of radiation mucositis in a patient with non-Hodgkin's lymphoma of Waldeyer's ring. Int J Radiat Oncol Biol Phys 1989; 17:907-8. [More details]

  14. Stein RS. Radiation-recall enteritis after actinomycin-D and adriamycin therapy. South Med J 1978; 71:960-1. [More details]

  15. Kitani H, Kosaka T, Fujihara T, Lindquist K, Elkind MM. The "recall effect" in radiotherapy: is subeffective, reparable damage involved? Int J Radiat Oncol Biol Phys 1990; 18:689-95. [More details]

  16. Azria D, Magne N, Zouhair A, Castadot P, Culine S, Ychou M, et al. Radiation recall: a well recognized but neglected phenomenon. Cancer Treat Rev 2005; 31:555-70. [More details]

  17. Camidge R, Price A. Characterizing the phenomenon of radiation recall dermatitis. Radiother Oncol 2001; 59:237-45. [More details]

  18. Burstein HJ. Side effects of chemotherapy. Case 1. Radiation recall dermatitis from gemcitabine. J Clin Oncol 2000; 18:693-4. [More details]

  19. Fogarty G, Ball D, Rischin D. Radiation recall reaction following gemcitabine. Lung Cancer 2001; 33:299-302. [More details]

  20. Jeter MD, Janne PA, Brooks S, Burstein HJ, Wen P, Fuchs CS, et al. Gemcitabine-induced radiation recall. Int J Radiat Oncol Biol Phys 2002; 53:394-400. [More details]

Article in PDF format
Look up who cited this article


Received February 7th, 2006 - Accepted March 13th, 2006

Keywords gemcitabine; Myositis; Pancreatic Neoplasms; Radiotherapy

Abbreviations CTV: clinical target volume; GTV: gross tumor volume; PTV: planning target volume

Correspondence
Marwan G Fakih
Department of Medicine
Roswell Park Cancer Institute
Elm and Carlton Sts
Buffalo, NY 14263
USA
Phone: +1-716.845.8189; +1-716.845.3362
Fax: +1-716.845.8008
E-mail: marwan.fakih@roswellpark.org

JOP Home page